August 2012
-
Marinomed Biotechnologie has announced that a randomized, double-blind placebo-controlled study of more than 200 patients suffering from the common cold found that patients who received a Carragelose-based nasal spray reduced the duration of symptoms by… Read more . . .
-
GlaxoSmithKline and Theravance have announced that a 12-week double-blind, parallel group Phase 3 study of their fluticasone furoate (FF)/vilanterol (VI) DPI (Breo/Relvar Ellipta) in almost 1,000 patients with moderate to severe asthma met its primary… Read more . . .
-
Spanish pharmaceutical company Almirall has issued a statement saying that the company will “reorganize” its European operations as a result of “economic driven decisions, made by country’s health authorities that have negatively affected the growth… Read more . . .
-
Hovione has announced that the addition of a MG2 FlexaLAB capsule filling machine will allow the company to expand its inhalation drug product development services. The FlexaLAB can fill up to 3,000 capsules per hour… Read more . . .
-
A study by the Cochrane Acute Respiratory Infections Group examined data from four studies involving almost 2,000 patients with acute sinusitis and determined that the benefits of intranasal corticosteroids (INCS) are “modest but clinically important.”… Read more . . .
-
Going to DDL 24 in Edinburgh next week? Gateway Analytical is inviting meeting attendees to a V.I.P. event at The Scotch Whisky Experience on the evening of December 11. The event includes a tour and… Read more . . .
-
According to Lightlake Therapeutics, initial results from a two-week PK study of intranasal naloxone for the treatment of opioid overdose shows that the nasal spray gets naloxone into the bloodstream as fast as injection. The… Read more . . .
-
Taiwan’s FDA has canceled marketing authorizations for calcitonin nasal sprays effective December 1 2013, and the products must be recalled within two months. According to the China Post, calcitonin nasal spray was first licensed in… Read more . . .
-
According to Bespak parent company Consort Medical, Bespak will construct a new dedicated facility at it’s King’s Lynn, UK site in order to meet production demands after signing a contract to manufacture a proprietary dry… Read more . . .
-
A study by Danish researchers published online November 25, 2013 by the Annals of Emergency Medicine found that intranasal fentanyl administered by ambulance workers prior to delivery of patients to the hospital appeared to be… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland